Short Interest in Achilles Therapeutics plc (NASDAQ:ACHL) Expands By 92.0%

Achilles Therapeutics plc (NASDAQ:ACHL) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 19,200 shares, a growth of 92.0% from the July 15th total of 10,000 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 65,300 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Trading of Achilles Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ACHL. Ikarian Capital LLC bought a new position in Achilles Therapeutics during the first quarter worth about $1,804,000. StemPoint Capital LP acquired a new position in shares of Achilles Therapeutics in the 1st quarter worth approximately $1,732,000. Acadian Asset Management LLC bought a new position in shares of Achilles Therapeutics during the 1st quarter worth approximately $350,000. Vestal Point Capital LP bought a new position in shares of Achilles Therapeutics during the 4th quarter worth approximately $96,000. Finally, XTX Topco Ltd boosted its stake in Achilles Therapeutics by 239.4% in the 2nd quarter. XTX Topco Ltd now owns 51,660 shares of the company’s stock valued at $42,000 after buying an additional 36,441 shares in the last quarter. Institutional investors own 56.38% of the company’s stock.

Achilles Therapeutics Stock Performance

Shares of ACHL stock opened at $0.76 on Thursday. The firm has a fifty day moving average of $0.83 and a 200-day moving average of $0.95. The stock has a market cap of $31.26 million, a price-to-earnings ratio of -0.48 and a beta of 1.32. Achilles Therapeutics has a 52-week low of $0.74 and a 52-week high of $1.76.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.